亚洲一区精品无码色成人,色悠久久久久久久综合网伊人

Ladirubicin

NMR下載 COA and HPLC MSDS下載
names：
(2S,3S,4S,6R)-6-(((1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl)oxy)-4-(aziridin-1-yl)-2-methyltetrahydro-2H-pyran-3-yl methanesulfonate
CAS號：
171047-47-5
MDL Number：
MF(分子式)： C29H31NO11S MW(分子量)： 601.62
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

貨品編碼	規(guī)格	純度	價格 (￥)	現(xiàn)價(￥)	特價(￥)	庫存描述	數(shù)量	總計 (￥)

大包裝詢價提供各種包裝，敬請垂詢
收藏商品商品點評加入購物車立即購買

快速詢價

收起

你想詢價的產品

*產品名稱：

CAS號：

產品編號：

需求描述：

請準確填寫您的聯(lián)系方式，以便為您提供最好的服務。

*公司名稱：

*電子郵箱：

聯(lián)系人：

*電話：

*驗證碼：

詢價

中文別名	Ladirubicin
英文別名	Ladirubicin;
CAS號	171047-47-5
Inchi	InChI=1S/C29H31NO11S/c1-13-28(41-42(3,37)38)18(30-8-9-30)10-20(39-13)40-19-12-29(36,14(2)31)11-17-21(19)27(35)23-22(26(17)34)24(32)15-6-4-5-7-16(15)25(23)33/h4-7,13,18-20,28,34-36H,8-12H2,1-3H3/t13-,18-,19-,20-,28+,29-/m0/s1
InchiKey	VMDWTZZCNDEKIO-CBNJBKGYSA-N
分子式 Formula	C29H31NO11S
分子量 Molecular Weight	601.62
溶解度Solubility
性狀	Solid powder
儲藏條件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

產品說明	Ladirubicin(CAS:171047-47-5):僅限應用于工業(yè)或者科學研究過程中非醫(yī)療目的，不應用于人類或動物的臨床診斷以及治過程療，該產品非藥用，非食用。
Introduction	Ladirubicin is an anthracyclines analogue, and the leading compound of alkylcyclines.
Application1
Application2
Application3

警示圖
危險性	Warning
危險性警示
安全聲明
安全防護
備注

[1]Soares PI, Dias SJ, Novo CM, Ferreira IM, Borges JP. Doxorubicin vs. ladirubicin: methods for improving osteosarcoma treatment. Mini Rev Med Chem. 2012 Oct;12(12):1239-49. PubMed PMID: 22512558.

[2]Pasello M, Hattinger CM, Stoico G, Manara MC, Benini S, Geroni C, Mercuri M, Scotlandi K, Picci P, Serra M. 4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): a promising new candidate for chemotherapeutic treatment of osteosarcoma patients. Eur J Cancer. 2005 Sep;41(14):2184-95. PubMed PMID: 16140527.

[3] Moneta D, Geroni C, Valota O, Grossi P, de Jonge MJ, Brughera M, Colajori E, Ghielmini M, Sessa C. Predicting the maximum-tolerated dose of PNU-159548 (4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin) in humans using CFU-GM clonogenic assays and prospective validation. Eur J Cancer. 2003 Mar;39(5):675-83. PubMed PMID: 12628848.

[4] Marchini S, Damia G, Broggini M, Pennella G, Ripamonti M, Marsiglio A, Geroni C. 4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548), a novel anticancer agent active against tumor cell lines with different resistance mechanisms. Cancer Res. 2001 Mar 1;61(5):1991-5. PubMed PMID: 11280757.

[5] Geroni C, Ripamonti M, Arrigoni C, Fiorentini F, Capolongo L, Moneta D, Marchini S, Della Torre P, Albanese C, Lamparelli MG, Ciomei M, Rossi R, Caruso M. Pharmacological and toxicological aspects of 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): a novel antineoplastic agent. Cancer Res. 2001 Mar 1;61(5):1983-90. PubMed PMID: 11280756.

6: Della Torre P, Podestà A, Imondi AR, Moneta D, Sammartini U, Arrigoni C, Terron A, Brughera M. PNU-159548, a novel cytotoxic antitumor agent with a low cardiotoxic potential. Cancer Chemother Pharmacol. 2001 Apr;47(4):355-60. PubMed PMID: 11345653.7: Breda M, Basileo G, Fonte G, Long J, James CA. Determination of 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyldaunorubicin+ ++ and its 13-hydroxy metabolite by direct injection of human plasma into a column-switching liquid chromatography system with mass spectrometric detection. J Chromatogr A. 1999 Aug 27;854(1-2):81-92. PubMed PMID: 10497930.8: de Jonge MJ, Verweij J, van der Gaast A, Valota O, Mora O, Planting AS, Mantel MA, Bosch SV, Lechuga MJ, Fiorentini F, Hess D, Sessa C. Phase I and pharmacokinetic studies of PNU-159548, a novel alkycycline, administered intravenously to patients with advanced solid tumours. Eur J Cancer. 2002 Dec;38(18):2407-15. PubMed PMID: 12460785.

對不起，暫無產品評價！

MSDS

SDS 1.0 中文

展開

SDS 1.0 英文

展開